Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company reported a strong cash position with INR 24,795 million in cash and equivalents as of December 31, 2023. Net cash position stood at INR 20,704 million after accounting for Cenexi's loans. Cash flow from operations during the nine months was robust at INR 6,228 million. Capex plans for expansion and operational improvements are being funded internally, including INR 810 million spent during the quarter. No indication of external financing requirements or new debt/equity raises was dis

Any current/future capex/capital investment/strategic investment?

Cenexi capex plan: Around EUR30 million planned for this year and next to replace equipment and increase capacity (Page 11). Gland Pharma capex: About INR300 crores expected in the next financial year for capacity expansions including Suite 9, Combi-line, and Pashamylaram Bag line (Page 12). Cenexi high-speed ampoule line: Ongoing project to enhance capacity and operational efficiencies (Page 6). Investments to build new high-speed lines, automate processes, and improve compliance at Cenexi to address operational issues and realize acquisition thesis over next 12-15 months (Page 4). Ongoing te

Future growth expectations in sales/revenue/volumes?

Gland Pharma targets mid-teens percentage growth over the next 3-5 years on an ex-Cenexi basis, driven by complex product filings and new product launches. The company expects continued revenue growth driven by U.S. market performance and incremental growth in Rest of the World (ROW) markets through tender wins (e.g., Saudi Arabia). Growth is supported by increasing CDMO (contract development and manufacturing organization) revenues due to product transfers from clients. The U.S. business has shown strong volume momentum with stable pricing and new product introductions, with the current

Future growth expectations in earnings/operating earnings/profits/EPS?

Gland Pharma targets mid-teens percentage growth on an ex-Cenexi basis over the next 2-3 years, driven by complex product launches and increased CDMO revenues. Sustainable EBITDA margin of around 10% is expected for Cenexi starting FY 2025, with break-even anticipated within 12-15 months from Q3 FY24. Cenexi's profitability hinges on operational improvements and capacity expansion, targeting EUR190-200 million revenues to generate positive EBITDA impact. U.S. market growth remains strong with volume-driven revenue sustainability and stable pricing environment. Indian market growth is l

Current/ Expected Orderbook/ Pending Orders?

The company has a strong order book and several transfer projects underway, indicating robust demand. Operational challenges and regulatory approval processes are causing some near-term delays in order execution. Capacity rebalancing and product line shifts are in progress to address these issues. Planned investment in new high-speed automated lines aims to improve capacity and operational efficiency. The acquisition of Cenexi and ongoing collaborations are expected to contribute incremental revenues in future. Overall, the business sees mid-teens growth target over the next 2-3 years, reflect

Gland Pharma LtdQ3 FY24Pharmaceuticals & Biotechnology

Gland Pharma Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,019.8P/E: 43.5Market Cap: ₹49.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Gland Pharma targets mid-teens percentage growth over the next 3-5 years on an ex-Cenexi basis, driven by complex product filings and new product launches.
The company expects continued revenue growth driven by U.S. market performance and incremental growth in Rest of the World (ROW) markets through tender wins (e.g., Saudi Arabia).
Growth is supported by increasing CDMO (contract development and manufacturing organization) revenues due to product transfers from clients.
The U.S. business has shown strong volume momentum with stable pricing and new product introductions, with the current quarterly run rate expected to sustain.
Cenexi's revenue growth is anticipated with additional projects and capacity enhancements, with break-even and profitability targets expected in 12-15 months.
India business is stable but less of a growth focus due to DPCO pricing regulations and smaller revenue contribution.
New product approvals in Australia, Europe, and South Africa will further contribute to growth.

Margin guidance

Category 3

Gland Pharma targets mid-teens percentage growth on an ex-Cenexi basis over the next 2-3 years, driven by complex product launches and increased CDMO revenues.
Sustainable EBITDA margin of around 10% is expected for Cenexi starting FY 2025, with break-even anticipated within 12-15 months from Q3 FY24.
Cenexi's profitability hinges on operational improvements and capacity expansion, targeting EUR190-200 million revenues to generate positive EBITDA impact.
U.S. market growth remains strong with volume-driven revenue sustainability and stable pricing environment.
Indian market growth is limited due to DPCO price controls, contributing a smaller revenue share.
Incremental depreciation and amortization impact due to Cenexi’s PPA is estimated at INR 90 to 140 million per quarter, slightly affecting consolidated profits.
Operational efficiencies, new product filings, capacity upgrades, and contract manufacturing initiatives underpin future profit growth.

See what Gland Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the transcript.
The company reported a strong cash position with INR 24,795 million in cash and equivalents as of December 31, 2023.
Net cash position stood at INR 20,704 million after accounting for Cenexi's loans.
Cash flow from operations during the nine months was robust at INR 6,228 million.
Capex plans for expansion and operational improvements are being funded internally, including INR 810 million spent during the quarter.
No indication of external financing requirements or new debt/equity raises was discussed during the call.

Order book

The company has a strong order book and several transfer projects underway, indicating robust demand.
Operational challenges and regulatory approval processes are causing some near-term delays in order execution.
Capacity rebalancing and product line shifts are in progress to address these issues.
Planned investment in new high-speed automated lines aims to improve capacity and operational efficiency.
The acquisition of Cenexi and ongoing collaborations are expected to contribute incremental revenues in future.
Overall, the business sees mid-teens growth target over the next 2-3 years, reflecting confidence in order inflow and backlog.

See what Gland Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Cenexi capex plan: Around EUR30 million planned for this year and next to replace equipment and increase capacity (Page 11).
Gland Pharma capex: About INR300 crores expected in the next financial year for capacity expansions including Suite 9, Combi-line, and Pashamylaram Bag line (Page 12).
Cenexi high-speed ampoule line: Ongoing project to enhance capacity and operational efficiencies (Page 6).
Investments to build new high-speed lines, automate processes, and improve compliance at Cenexi to address operational issues and realize acquisition thesis over next 12-15 months (Page 4).
Ongoing tech transfer and approval processes for new programs at Cenexi expected to add EUR30-40 million incremental revenue medium-term (Page 4).

Track Gland Pharma Ltd — get its next earnings analysis in your feed

How does Gland Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGland Pharma Ltd

Rev 3Mar 3

See where Gland Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Gland Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Gland Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Gland Pharma Ltd Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Gland Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season